Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial

Cancer Communications

Ke-Ming Wang¹  Chun-Mei Shi²  Jue-Ping Feng³  Yu-Xian Bai⁶  Hao Yu⁷  Jian-Ping Xiong⁸  Chang-Ping Wu⁹  Yi Ba^1,10  Jin Li^1,11  Dong Wang^1,12  Ke-Feng Ding^1,13  Li-Wen Ma^1,14  Gang Wu^1,15  Rui-Hua Xu^1,16  Jin-Wan Wang^1,17  Jian Lei^1,18  Jing-Wang Bi^1,19  Li-Zhu Lin^2,20  Qing Yang^2,21  Lin Shen^2,22  Yun-Peng Liu^2,23 

[1]Institute, Beijing, P. R. China

[2]Cancer Center of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China

[3]Cancer Center, Daping Hospital and Institute of Surgery Research, Third Military Medical University, Chongqing, P. R. China

[4]Department of Clinical Medicine, Jiangsu Hengrui Medicine Co., Ltd, Lianyungang, P. R. China

[5]Department of Epidemic and Health Statistics, Nanjing Medical University, Nanjing, P. R. China

[6]Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, P. R. China

[7]Department of Gastrointestinal Surgery, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, P. R. China

[8]Department of Medical Oncology, Chinese Academy of Medical Sciences Cancer Hospital, Beijing, P. R. China

[9]Department of Medical Oncology, First Affiliated Hospital of Nanchang University, Nanchang, P. R. China

[10]Department of Medical Oncology, First Hospital of China Medical University, Shenyang, P. R. China

[11]Department of Medical Oncology, First People’

[12]Department of Medical Oncology, Fudan University Cancer Hospital, Shanghai, P. R. China

[13]Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, P. R. China

[14]Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, P. R. China

[15]Department of Medical Oncology, Second Affiliated Hospital of Nanjing Medical University, Nanjing, P. R. China

[16]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, P. R. China

[17]Department of Oncology, First Affiliated Hospital of Guangzhou Medical University of Chinese Medicine, Guangzhou, P. R. China

[18]Department of Oncology, Jinan Military General Hospital, Jinan, P. R. China

[19]Department of Oncology, PuAi Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China

[20]Department of Surgical Oncology, Second Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou, P. R. China

[21]Department of Tumor Chemotherapy and Radiology, Peking University Third Hospital, Beijing, P. R. China

[22]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital &

[23]s Hospital of Changzhou, Changzhou, P. R. China

关键词: Colorectal cancer;    Famitinib;    Efficacy;    Safety;   

DOI  :  10.1186/s40880-017-0263-y

学科分类：肿瘤学

来源: Springer

【 授权许可】

CC BY